BiotechTube
NeoVirTech

NeoVirTech

Paris, France· Est.
neovirtech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

NeoVirTech is a specialized virology services and technology company built around its breakthrough ANCHOR™ imaging platform. This technology enables real-time, live-cell visualization of viral infection cycles, providing a powerful tool for high-content screening in antiviral discovery, validating oncolytic viruses, and measuring disinfection efficacy. Operating from BSL2 and BSL3 facilities, the company serves pharmaceutical, biotech, and academic clients worldwide with a portfolio of over 30 engineered viruses. Its business model is primarily service-based, positioning it as a critical enabler for the broader virology and antiviral therapeutics sector.

Infectious DiseaseOncology

Technology Platform

ANCHOR™ technology: a molecular tool for real-time, live-cell imaging and quantification of virus infection and replication using fluorescently tagged recombinant viruses. Integrated with high-content screening microscopy.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing markets for antiviral drug discovery, oncolytic virotherapies, and gene therapy vector optimization create strong demand for NeoVirTech's enabling imaging services.
Increased focus on pandemic preparedness and disinfection standards post-COVID-19 opens a niche but sustained market for its validation testing services.

Risk Factors

Revenue is dependent on the fluctuating R&D budgets of biopharma clients, creating potential volatility.
Operating high-containment BSL3 labs carries significant safety, regulatory, and liability risks.
The company faces competition from alternative screening technologies and internal capabilities of large clients.

Competitive Landscape

NeoVirTech competes with other contract research organizations (CROs) offering virology services, as well as academic core facilities. Its key differentiator is the proprietary ANCHOR™ live-cell imaging technology, which offers unique kinetic data compared to standard endpoint assays. Competition also comes from in-house capabilities at large pharmaceutical companies and alternative high-content screening platforms.

More companies in Cell & Gene Therapy →More companies in France →